KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Long-Term Deferred Tax (2016 - 2019)

Bio-Rad Laboratories has reported Long-Term Deferred Tax over the past 11 years, most recently at $138.0 million for Q4 2019.

  • Quarterly Long-Term Deferred Tax rose 80.87% to $138.0 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $138.0 million through Dec 2019, up 80.87% year-over-year, with the annual reading at $138.0 million for FY2019, 80.87% up from the prior year.
  • Long-Term Deferred Tax was $138.0 million for Q4 2019 at Bio-Rad Laboratories, up from $76.3 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $138.0 million in Q4 2019 and troughed at $76.3 million in Q4 2018.
  • The 5-year median for Long-Term Deferred Tax is $99.5 million (2015), against an average of $102.2 million.
  • Year-over-year, Long-Term Deferred Tax plummeted 32.77% in 2017 and then surged 80.87% in 2019.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $99.5 million in 2015, then grew by 18.39% to $117.8 million in 2016, then plummeted by 32.77% to $79.2 million in 2017, then decreased by 3.66% to $76.3 million in 2018, then soared by 80.87% to $138.0 million in 2019.
  • Per Business Quant, the three most recent readings for BIO's Long-Term Deferred Tax are $138.0 million (Q4 2019), $76.3 million (Q4 2018), and $79.2 million (Q4 2017).